10 瓶組庫存 2省 17%Tesamorelin 5 mg
穩定化 GHRH 類似物
Tesamorelin GHRH analogue research peptide, Australian-shipped. Lab-verified ≥99% purity.
僅供研究使用。 本化合物嚴格用於體外研究及實驗室用途,不得供人體食用或治療用途。購買即確認您為合格研究者,並同意我們的 完整免責聲明。
只剩 2 組
穩定化的生長激素釋放激素類似物,文獻關注其對內臟脂肪組織及 IGF-1 軸活性的影響(研究模型)。
Tesamorelin is a stabilised analogue of growth-hormone-releasing hormone (GHRH) — modified to extend its half-life relative to native GHRH. It is one of the most studied GHRH-analogue research peptides and the only one of its class to have undergone regulatory approval in any jurisdiction (for HIV-associated lipodystrophy, in the US, under the brand name Egrifta). Quantum Labs supplies Tesamorelin as a lyophilised powder for Australian research applications.
Research on Tesamorelin has covered models of growth-hormone secretion, body composition, lipid metabolism, and IGF-1 dynamics. Material is HPLC-verified to ≥99% purity and ships from Australian stock; supplied for laboratory research use only.
作用機制
文獻關注其選擇性結合 GHRH 受體並具有延長半衰期。研究與研究族群內臟脂肪指標降低及 IGF-1 升高相關。
經 HPLC 驗證,純度規格 ≥99%。由獲認可的第三方實驗室獨立檢測。
Tesamorelin — 常见問題
What is Tesamorelin?
Tesamorelin is a stabilised synthetic analogue of growth-hormone-releasing hormone (GHRH). It is studied in growth-hormone research and pre-clinical models of metabolic regulation and body composition.
Is Tesamorelin legal in Australia?
Tesamorelin is not approved as a therapeutic in Australia and remains available for research and laboratory use when supplied without therapeutic representation. Quantum Labs supplies Tesamorelin for research use only.
What is the difference between Tesamorelin and CJC-1295?
Both are GHRH-analogue research peptides. CJC-1295 has a longer half-life and a stronger ability to extend the duration of GH pulses; Tesamorelin's modifications produce a shorter-acting but well-characterised GHRH-mimicking profile. They are studied as parallel research tools for different aspects of GHRH-pathway signalling.
What is the typical Tesamorelin research dosage?
Published clinical research (in the US, for the approved indication) has used 2 mg daily subcutaneous Tesamorelin. Research-protocol dosing varies by model. Human therapeutic dosing is not established in Australia.
與 Tesamorelin 相關的指南
研究者還會瀏覽
精選10 瓶組省 25%Retatrutide
凍乾粉末10 mg · 8 strengths
GLP-1 / GIP / 升糖素三促效劑研究用胜肽
收錄於 1 套組合
10 瓶組省 17%5-Amino-1MQ
凍乾粉末50 mg · 3 strengths
NNMT 抑制劑研究化合物


